Frontier Pharma: Ovarian Cancer Report - What Are The Current Unmet Needs That The Pipeline Needs To Address - Research and Markets

Apr 20, 2016, 15:48 ET from Research and Markets

DUBLIN, April 21, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation" report to their offering. 

     (Logo: )

Ovarian Cancer Treatment Pipeline Offers Promising Alternatives to Chemotherapy 

Despite the currently high level of unmet need in the ovarian cancer therapeutic market, a strong pipeline of 462 diverse and innovative products in active development signals significant potential for alternatives to chemotherapy, according to this latest research report. "Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation" states that as the market becomes more diverse, it will become less reliant on indiscriminate and highly cytotoxic chemotherapy regimens, which do not target specific proteins in aberrant pathways in ovarian cancer. 

Joshua Libberton, one of the report analysts, says that despite limited therapeutic options for ovarian cancer patients at the moment, almost 52% of ovarian cancer products in active development in the pipeline are considered to be first-in-class, as they have a molecular target not associated with any marketed products. 

Libberton explains: As the current ovarian cancer market has a large generic presence, and relatively few novel active pharmaceutical ingredients, the market has stagnated, leaving a large portion of the ovarian cancer population with significant unmet needs. Currently, ovarian cancer has the highest mortality rate of all gynaecological cancers and is fatal in a majority of patients, rendering it imperative that more effective therapies are developed. 

According to this research, the high proportion of first-in-class innovation implies that the industry is pursuing novel approaches to treatment and reducing the focus on established therapies. Although innovation to date has been slow, greater disease understanding and awareness has created an environment in which it will thrive. 

Libberton continues: In addition to the use of existing platinum-based chemotherapy, treatments such as anti-angiogenic treatments and Poly ADP Ribose Polymerase inhibitors are expected to have a positive impact on ovarian cancer survival in particular patient subsets. The pipeline is showing clear signs of innovation in ovarian cancer treatment, with many products deviating away from standard chemotherapy targets, and a high proportion of first-in-class drugs. 

Scope of the report: 

Chemotherapy based regimens continue to dominate the market, which has seen few new entrants over the past decade. Lynparza (olaparib) is a key new entrant; however it is only effective in a small patient subset. 
- What survival benefits do current therapies provide? 
- What are the current unmet needs that the pipeline needs to address? 

The pipeline places increased focus on targeted therapies, including a large number of therapies targeting common oncogenic pathways and signaling intermediates such as PI3K/Akt. 
- What potential do mAbs have in ovarian cancer treatment? 
- Will pipeline diversity translate to clinically and commercially successful therapies? 
- How are common target families, such as intracellular signal transduction associated with pathophysiology? 

52% of pipeline products act on a first-in-class target, which is higher than the oncology and industry averages. 
- Do first-in-class products show strong progression into the later stages? 
- Why is the greatest number of first-in-class products seen in signal transduction? 

First-in-class products differ substantially in their clinical potential, based on their alignment to disease causing pathways 
- How well are first-in-class targets, such as Notch, aligned to known disease causing pathways? 
- Which targets are specifically found in early-stage development? 
- What is the industry-wide interest in these targets? 

Co-development deals for first-in-class products are typically higher value than non-first-in-class counterparts. 
- To what extent does first-in-class status influence deal value and phase? 
- Can biologics command a greater deal value than other molecule types? 

For more information visit

Media Contact:  

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets